Search Results - "Boruchov, Adam M."

Brincidofovir for Polyomavirus-Associated Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation by Papanicolaou, Genovefa A., MD, Lee, Yeon Joo, MD, Young, James W., MD, Seshan, Surya V., MB BS, Boruchov, Adam M., MD, Chittick, Gregory, BS, Momméja-Marin, Herve, MD, Glezerman, Ilya G., MD

“…Polyomavirus-associated nephropathy (PVAN) is common in patients who have undergone kidney transplantation and has been reported in hematopoietic stem cell…”
Get full text

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study by Davids, Matthew S, Kim, Haesook T, Nicotra, Alyssa, Savell, Alexandra, Francoeur, Karen, Hellman, Jeffrey M, Bazemore, Josie, Miskin, Hari P, Sportelli, Peter, Stampleman, Laura, Maegawa, Rodrigo, Rueter, Jens, Boruchov, Adam M, Arnason, Jon E, Jacobson, Caron A, Jacobsen, Eric D, Fisher, David C, Brown, Jennifer R

“…Patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib…”
Get full text

Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts by Mehta‐Shah, Neha, Lunning, Matthew A., Moskowitz, Alison J., Boruchov, Adam M., Ruan, Jia, Lynch, Peggy, Hamlin, Paul A., Leonard, John, Matasar, Matthew J., Myskowski, Patricia L., Marzouk, Evan, Nair, Sumithra, Sholklapper, Tamir, Minnal, Veena, Palomba, Maria L., Vredenburgh, James, Kumar, Anita, Noy, Ariela, Straus, David J., Zelenetz, Andrew D., Schoder, Heiko, Rademaker, Jurgen, Schaffer, Wendy, Galasso, Natasha, Ganesan, Nivetha, Horwitz, Steven M.

“…Romidepsin (histone deacetylase inhibitor), lenalidomide (immunomodulatory agent), and carfilzomib (proteasome inhibitor), have efficacy and lack cumulative…”
Get full text

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions by Boruchov, Adam M, Heller, Glenn, Veri, Maria-Concetta, Bonvini, Ezio, Ravetch, Jeffrey V, Young, James W

“…Human monocyte-derived DCs (moDCs) and circulating conventional DCs coexpress activating (CD32a) and inhibitory (CD32b) isoforms of IgG Fcgamma receptor…”
Get full text

Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis by Boruchov, Adam M

“…Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoeisis and an increased risk of…”
Get full text

Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83 by Sénéchal, Brigitte, Boruchov, Adam M., Reagan, John L., Hart, Derek N.J., Young, James W.

“…We have studied the mechanisms by which human cytomegalovirus (HCMV) infection of monocyte-derived dendritic cells (moDCs) contribute to immune suppression…”
Get full text

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy by Zhou, Ping, Comenzo, Raymond L., Olshen, Adam B., Bonvini, Ezio, Koenig, Scott, Maslak, Peter G., Fleisher, Martin, Hoffman, James, Jhanwar, Suresh, Young, James W., Nimer, Stephen D., Boruchov, Adam M.

“…Despite advances in therapy, many patients with systemic light-chain amyloidosis (AL) die within 3 years from diagnosis. The humanized 2B6 monoclonal antibody…”
Get full text

Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis: The Changing Landscape of Secondary ITP by BORUCHOV, Adam M

Get full text

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma by Mehta-Shah, Neha, Lunning, Matthew Alexander, Boruchov, Adam M., Ruan, Jia, Nair, Sumithra, Lynch, Peggy, Byrne, Regina, Moskowitz, Alison J., Matasar, Matthew J., Gerecitano, John F., Hamlin, Paul A., Leonard, John, Moskowitz, Craig H., Myskowski, Patricia L., Querfeld, Christiane, Nolan, Patrick, Palomba, Maria Lia, Straus, David J., Zelenetz, Andrew David, Horwitz, Steven M.

“…Abstract only…”
Get full text

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results by Lunning, Matthew Alexander, Ruan, Jia, Nair, Sumithra, Boruchov, Adam M., Byrne, Regina, Gerecitano, John F., Hamlin, Paul A., Inserra, Beth, Leonard, John, Lynch, Peggy, Matasar, Matthew J., Moskowitz, Alison J., Moskowitz, Craig, Myskowski, Patricia L., Nolan, Patrick, Palomba, Maria Lia, Quefeld, Christiane, Straus, David J., Zelenetz, Andrew David, Horwitz, Steven M.

“…Abstract only…”
Get full text

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM) by Zhou, Ping, Boruchov, Adam M, Hoffman, James E., Mo, Qianxing, Olshen, Adam, Glasner, Evan, Bonvini, Ezio, Koenig, Scott, Drieghe, Ellen, Fleisher, Martin, Maslak, Peter, Hassoun, Hani, Cohen, Adam D, Landau, Heather, Young, James W., Jhanwar, Suresh C, Nimer, Stephen D, Comenzo, Raymond L

“…Intraclonal heterogeneity (IH) in MM may provide a basis for the selection of resistance to therapy that occurs over time. Model systems to study IH in MM have…”
Get full text